Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-drug Conjugate for Treatment of CLDN18.2 Positive Cancers

By sjmartinez • October 4, 2023

O'Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, Hoffstrom B, Luo T, Ayala R, Chau K, Liang M, Madrid AM, Donahue TR, Glaspy JA, Presta L, Slamon DJ. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-drug Conjugate for Treatment of CLDN18.2 Positive Cancers. Mol Cancer Ther. 2023 Oct 3. doi: 10.1158/1535-7163.MCT-23-0353. Epub ahead of print. PMID: 37788341.

Tags: Hematology/Oncology, Publications

Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study

Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van[...]

Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies

Fuchs SP, Mondragon PG, Zabizhin R, Tomer S, Wang L, Cook E, Dudley DM, Weisgrau KL, Furlott J, Coonen J, Alexander E, Xie J, Gao[...]

Lower dose and weekly schedules of selinexor in multiple myeloma – updated evidence on safety and efficacy

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on[...]